US4888178A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Galenic formulations with programmed release containing naproxen
Assignee: Alfa Wasserman SpA
•
Filing: 1989-04-12
•
Granted: 1989-12-19
•
Expires: 2009-04-12
Abstract
Abstract A galenic formulations are disclosed with programmed release, to be administered orally containing as the active ingredient a compound having antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid, and pharmaceutically acceptable salts thereof. In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action and reach the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow therapeutic coverage until subsequent administration. The therapeutic coverage can even last twenty-four hours. Thus, the new galenic formulations object of the present invention are suitable for administration one a day.
Inventors
- 👤 Leone G. Rotini
- 👤 Egidio Marchi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 16:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K9/00; A61K9/20; A61K9/2072; A61K9/2077; A61K9/48; A61K9/50; A61K9/5084; A61P; A61P25/00; A61P25/04; A61P29/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
98 words
A galenic formulation for oral administration having a programmed release and containing naproxen as an active ingredient, which is formed by a mixture comprising: (a) a granulate having immediate release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with a binding agent, a disintegrating agent, and a lubricating agent; and (b) a granulate having a controlled release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with hydrogenated castor oil and ethylcellulose as retarding agents.
Claim 2
Dependent Claim
98 words
A galenic formulation for oral administration having a programmed release and containing naproxen as an active ingredient, which is formed by a mixture comprising: (a) a granulate having immediate release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with a binding agent, a disintegrating agent, and a lubricating agent; and (b) a granulate having a controlled release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with hydrogenated castor oil and ethylcellulose as retarding agents.
Claim 3
Dependent Claim
32 words
The galenic formulation of claim 1, which is in the form of a tablet, a capsule, a sugard coated tablet or a granulate for suspension or for solution in suitable liquid media.
Claim 4
Dependent Claim
30 words
The galenic formulation of claim 1, wherein said binding agent is a member selected from the group consisting of polyvinylpyrrolidone, carboxymethylcellulose, microcrystalline cellulose, lactose, saccharose, mannitol, gumarabic, pectin, and gelatin.
Claim 5
Dependent Claim
27 words
The galenic formulation of claim 1, wherein said disintegrating agent is a member selected from the group consisting of starch, sodium starch glycolate, alginates, and reticutaled polyvinylpirrolidone.
Claim 6
Dependent Claim
27 words
The galenic formulation of claim 1, wherein said lubricating agent is a member selected from the group consisting of talc, magnesium stearate, stearic acid, and silica gel.
Claim 7
Dependent Claim
178 words
A galenic formulation for oral administration having a programmed release and containing naproxen as an active ingredient, which is formed by a mixture comprising: (a) a granulate having immediate release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with a binding agent, a disintegrating agent, and a lubricating agent, wherein said immediate release granulate is composed of about 60% to about 70% by weight of naproxen, about 20% to about 30% by weight of a binding agent; about 8% to about 12% by weight of a disintegrating agent, and about 0.2% to about 1% by weight of a lubricating agent; and (b) a granulate having a controlled release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with hydrogenated castor oil and ethylcellulose as retarding agents, wherein said controlled release granulate is composed of about 60% to about 70% by weight of naproxen and about 30% to about 40% by weight of said retarding agents.
Claim 8
Dependent Claim
178 words
A galenic formulation for oral administration having a programmed release and containing naproxen as an active ingredient, which is formed by a mixture comprising: (a) a granulate having immediate release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with a binding agent, a disintegrating agent, and a lubricating agent, wherein said immediate release granulate is composed of about 60% to about 70% by weight of naproxen, about 20% to about 30% by weight of a binding agent; about 8% to about 12% by weight of a disintegrating agent, and about 0.2% to about 1% by weight of a lubricating agent; and (b) a granulate having a controlled release including from about 30% to about 70% by weight of the total amount of naproxen in said formulation in admixture with hydrogenated castor oil and ethylcellulose as retarding agents, wherein said controlled release granulate is composed of about 60% to about 70% by weight of naproxen and about 30% to about 40% by weight of said retarding agents.
Claim 9
Dependent Claim
32 words
The galenic formulation of claim 6, which is in the form of a tablet, a capsule, a sugar coated tablet or a granulate for suspension or for solution in suitable liquid media.
Claim 10
Dependent Claim
30 words
The galenic formulation of claim 6, wherein said binding agent is a member selected from the group consisting of polyvinylpyrrolidone, carboxymethylcellulose, microcrystalline cellulose, lactose, saccharose, mannitol, gumarabic, pectin, and gelatin.
Claim 11
Dependent Claim
27 words
The galenic formulation of claim 6, wherein said disintegrating agent is a member selected from the group consisting of starch, sodium starch glycolate, alginates, and reticulated polyvinylpirrolidone.
Claim 12
Dependent Claim
27 words
The galenic formulation of claim 6, wherein said lubricating agent is a member selected from the group consisting of talc, magnesium stearate, stearic acid, and silica gel.
Claim 13
Dependent Claim
91 words
The galenic formulation of claim 6, wherein said granulate (a) is composed of 60% to 70% by weight of naproxen, 17% to 23% by weight of lactose, 3% to 7% by weight of polyvinylpyrrolidone, 4% to 8% by weight of maize starch, 3% to 6% by weight of sodium starch glycolate, and 0.2% to 0.5% by weight of magnesium stearate; and said granulate (b) is composed of 60% to 70% by weight of naproxen, 20% to 30% by weight of hydrogenated castor oil, and 6% to 12% by weight of ethylcellulose.
Claim 14
Dependent Claim
71 words
The galenic formulation of claim 6, which is in the form of a tablet containing 750 mg of naproxen, wherein the composition of granulate (a) is the following: ______________________________________
component mg
______________________________________
naproxen 300
lactose 88.8
polyvinylpyrrolidone 18
maize starch 30
sodium starch glycolate 18
magnesium stearate 1.2
______________________________________ and the composition of granulate (b) is the following: ______________________________________
component mg
______________________________________
naproxen 450
hydrogenated castor oil 171
ethylcellulose 54
______________________________________
Claim 15
Dependent Claim
71 words
The galenic formulation of claim 6, which is in the form of a tablet containing 500 mg of naproxen, wherein the composition of granulate (a) is the following: ______________________________________
component mg
______________________________________
naproxen 300
lactose 88.8
polyvinylpyrrolidone 18
maize starch 30
sodium starch glycolate 18
magnesium stearate 1.2
______________________________________ and the composition of granulate (b) is the following: ______________________________________
component mg
______________________________________
naproxen 200
hydrogenated castor oil 76
ethylcellulose 24
______________________________________
Claim 16
Dependent Claim
84 words
The galenic formulation of claim 6, which is in the form of a granular for solution or suspension containing 500 mg of naproxen, wherein the composition of granulate (a) is the following: ______________________________________
component mg
______________________________________
naproxen 250
lactose 74
polyvinylpyrrolidone 15
maize starch 25
sodium starch glycolate 15
magnesium stearate 1
______________________________________ and the composition of granulate (b) is the following: ______________________________________
component mg
______________________________________
naproxen 250
hydrogenated castor oil 95
ethylcellulose 30
______________________________________ and said formulation contains 2000 mg of orange granular.
Claim 17
Dependent Claim
71 words
The galenic formulation of claim 6, which is in the form of a capsule containing 375 mg of naproxen, wherein the composition of granulate (a) is the following: ______________________________________
component mg
______________________________________
naproxen 175
lactose 55.4
polyvinylpyrrolidone 11.2
maize starch 18.7
sodium starch glycolate 11.2
magnesium stearate 0.8
______________________________________ and the composition of granulate (b) is the following: ______________________________________
component mg
______________________________________
naproxen 200
hydrogenated castor oil 76
ethylcellulose 24
______________________________________
References Cited (Backward Citations)
US2793979A
Cited
US3044938A
Cited
US4012498A
Cited
US4167588A
Cited
US4572833A
Cited
US4720387A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-12-18 | 1993-06-19 | 1993-12-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-12-18 | 1997-06-19 | 1997-12-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-12-18 | 2001-06-19 | 2001-12-19 | $7700.00 | Window Closed / Lapsed |